""Our study indicates that although quetiapine did not worsen movement in demented patients with parkinsonian features, it did not result in improvement of agitation or psychosis any greater than placebo," lead researcher Dr. Roger Kurlan told Reuters Health."

"Kurlan of the University of Rochester, New York and colleagues conducted a clinical trial involving 23 patients with dementia with Lewy bodies, 9 patients with Parkinson's disease with dementia, and 8 patients with Alzheimer's disease with parkinsonian features."

"The subjects were randomly assigned to receive quetiapine (120 milligrams per day) or placebo. The drug was well tolerated, but at 10 weeks there were no between-group differences in scores on the Brief Psychiatric Rating Scale, according to the report in the current issue of Neurology."

"The researchers note that a number of factors including an unexpectedly large
... read the whole article